Evaluation of a quantitative serum Aspergillus fumigatus-specific IgM assay for diagnosis of chronic pulmonary aspergillosis
© 2018 John Wiley & Sons Ltd..
BACKGROUND: The early diagnosis of chronic pulmonary aspergillosis (CPA) remains challenging. Currently, a new quantitative IgM antibody assay that enveloped purified galactomannan extracted from Aspergillus fumigatus as antigen was commercially available in China, but its diagnostic value remains to be established.
METHODS: To evaluate the role of this commercial IgM assay for diagnosis of CPA, a multi-center prospective study was performed in 12 hospitals in Zhejiang Province, from January 1 to December 31, 2016. Adult inpatients without severe immunocompromised condition and those with persistent clinical symptoms/radiological findings ≥3 months or a consistent appearance in chest CT that was suggestive of CPA were included. The clinical data were compiled using a structured questionnaire.
RESULTS: A total of 87 cases were enrolled, including 43 CPA. The sensitivity ranged from 16.3% to 46.5%, and the specificity from 77.3% to 95.5% when cutoffs were from 50 to 80 arbitrary unit (AU)/mL. The receiver operating characteristic analysis revealed an area under the curve of 0.627. When a cutoff of 38.12 AU/mL was applied, the sensitivity and specificity were 69.8% and 56.8%, respectively, which represents the best performance.
CONCLUSIONS: To our knowledge, this study was the first to evaluate this commercial A. fumigatus-specific IgM antibody assay in CPA patients in China and indicates that this IgM assay has a limited value and should not be a prior recommendation for CPA diagnosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
The clinical respiratory journal - 12(2018), 11 vom: 22. Nov., Seite 2566-2572 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yao, Yake [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CPA |
|---|
| Anmerkungen: |
Date Completed 18.03.2019 Date Revised 18.03.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/crj.12957 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM288291166 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM288291166 | ||
| 003 | DE-627 | ||
| 005 | 20231225055934.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/crj.12957 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0960.xml |
| 035 | |a (DE-627)NLM288291166 | ||
| 035 | |a (NLM)30191673 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yao, Yake |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of a quantitative serum Aspergillus fumigatus-specific IgM assay for diagnosis of chronic pulmonary aspergillosis |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.03.2019 | ||
| 500 | |a Date Revised 18.03.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2018 John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND: The early diagnosis of chronic pulmonary aspergillosis (CPA) remains challenging. Currently, a new quantitative IgM antibody assay that enveloped purified galactomannan extracted from Aspergillus fumigatus as antigen was commercially available in China, but its diagnostic value remains to be established | ||
| 520 | |a METHODS: To evaluate the role of this commercial IgM assay for diagnosis of CPA, a multi-center prospective study was performed in 12 hospitals in Zhejiang Province, from January 1 to December 31, 2016. Adult inpatients without severe immunocompromised condition and those with persistent clinical symptoms/radiological findings ≥3 months or a consistent appearance in chest CT that was suggestive of CPA were included. The clinical data were compiled using a structured questionnaire | ||
| 520 | |a RESULTS: A total of 87 cases were enrolled, including 43 CPA. The sensitivity ranged from 16.3% to 46.5%, and the specificity from 77.3% to 95.5% when cutoffs were from 50 to 80 arbitrary unit (AU)/mL. The receiver operating characteristic analysis revealed an area under the curve of 0.627. When a cutoff of 38.12 AU/mL was applied, the sensitivity and specificity were 69.8% and 56.8%, respectively, which represents the best performance | ||
| 520 | |a CONCLUSIONS: To our knowledge, this study was the first to evaluate this commercial A. fumigatus-specific IgM antibody assay in CPA patients in China and indicates that this IgM assay has a limited value and should not be a prior recommendation for CPA diagnosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a CPA | |
| 650 | 4 | |a chronic pulmonary aspergillosis | |
| 650 | 4 | |a diagnostic value | |
| 650 | 4 | |a serum Aspergillus fumigatus-specific IgM antibody assay | |
| 650 | 7 | |a Immunoglobulin M |2 NLM | |
| 700 | 1 | |a Zhou, Hua |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Yihong |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Qing |e verfasserin |4 aut | |
| 700 | 1 | |a Ye, Jian |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Yiqi |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Guohua |e verfasserin |4 aut | |
| 700 | 1 | |a Lou, Haiyan |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Yunsong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Jianying |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The clinical respiratory journal |d 2007 |g 12(2018), 11 vom: 22. Nov., Seite 2566-2572 |w (DE-627)NLM19646837X |x 1752-699X |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2018 |g number:11 |g day:22 |g month:11 |g pages:2566-2572 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/crj.12957 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2018 |e 11 |b 22 |c 11 |h 2566-2572 | ||